The latest open-label, randomized, controlled, phase 3 study that was published in 2022, ARIEL 4, supports the usage of rucaparib as an alternative treatment option to chemotherapy for patients with relapsed, BRCA1/2 mutated ovarian cancers who have received at least two cycles of previous chemotherapy regimens. This evidence concerns the gene BRCA1 and ovarian carcinoma.